Zusammenfassung
Die Pathogenese der meisten Vaskulitiden beinhaltet die Einbeziehung multipler Organe und konsekutiv klinische Manifestationen in allen Fachdisziplinen, folglich handelt es sich meist um hochkomplexe Krankheitsbilder. Durch frühzeitige Diagnose und Therapie dieser Erkrankungen können relevante Komplikationen vermieden und die Prognose der Patienten deutlich verbessert werden. Kollegen aller Fachdisziplinen sollten bei anhaltenden Beschwerden, die auf etablierte Therapien nicht angemessen reagieren, immer eine Vaskulitis mit in Betracht ziehen. Umgekehrt sollte bei bekannter Vaskulitis jeder potenziell beteiligte Fachbereich in die Statuserhebung und die weitere Therapie eingebunden sein. Für die Langzeitprognose und kontinuierliche Therapieüberwachung sollte das Regime in der Hand eines Arztes liegen, der als Ansprechpartner für den Patienten da ist und in regelmäßigen Abständen mit den beteiligten Kollegen in Austausch steht.
Abstract
Due to the underlying etiopathology of systemic vasculitis, a complex and chronic disabling disease, almost all organs of the body can be affected. As a consequence patients with manifestations of vasculitis may present to physicians from nearly all disciplines. Relevant complications can be avoided and the prognosis of the patient can be greatly improved if the diagnosis and treatment are established early. Physicians in all disciplines should always consider a possible vasculitis if signs and symptoms continue despite initiation of established treatment. On the other hand physicians from all potentially involved disciplines should examine patients with diagnosed vasculitis and should be jointly involved in the status documentation and therapeutic approach. For the long-term prognosis and continuous supervision of treatment the regimen should be under the control of one physician who is available as the contact person for the patient and is in close cooperation with the other colleagues involved at regular intervals.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Barra LJ, Bateman EA, Rohekar S, Pagnoux C, Moradizadeh M (2016) Assessment of work limitations and disability in systemic vasculitis. Clin Exp Rheumatol 34(3 Suppl 97):111–114
Benarous L, Terrier B, Laborde-Casterot H, Bérezné A, Dunogué B, Cohen P et al (2017) Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. Clin Exp Rheumatol 35(1):40–46
Suresh E (2006) Diagnostic approach to patients with suspected vasculitis. Postgrad Med J 82:483–488
Prior JA, Ranjbar H, Belcher J, Mackie SL, Helliwell T, Liddle J et al (2017) Diagnostic delay for giant cell arteritis—a systematic review and meta-analysis. Bmc Med 15(1):120
Saleh M, Turesson C, Englund M, Merkel PA, Mohammad AJ (2016) Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol 43(8):1559–1565
Manzo C (2016) Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica. Reumatologia 54(5):236–238
Naderi N, Mohammad AJ, Turesson C (2017) Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution, and predictors. Scand J Rheumatol 46(3):215–221
Maritati F, Iannuzzella F, Pavia MP, Pasquali S, Vaglio A (2016) Kidney involvement in medium- and large-vessel vasculitis. J Nephrol 29:495–505
Talarico R, Boiardi L, Pipitone N, D’Ascanio A, Stagnaro C, Ferrari C et al (2014) Isolated aortitis versus giant cell arteritis: are they really two sides of the same coin? Clin Exp Rheumatol 32(SUPPL.82):55–58
Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL et al (2015) Large-vessel giant cell arteritis: a cohort study. Rheumatology 54(3):463–470
Siemonsen S, Brekenfeld C, Holst B, Kaufmann-Buehler A‑K, Fiehler J, Bley TA (2015) 3T MRI reveals extra-and intracranial involvement in giant cell arteritis. AJNR Am J Neuroradiol 36(1):91–97
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11. https://doi.org/10.1002/art.37715
Jarrot PA, Kaplanski G (2016) Pathogenesis of ANCA-associated vasculitis: an update. Autoimmun Rev 15:704–713
Jennette JC, Falk RJ, Gasim AH (2011p) Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens 20:263–270
King C, Harper L (2017) Avoidance of Harm from treatment for ANCA-associated Vasculitis. Curr Treatm Opt Rheumatol 3(4):230–243
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med 363(3):221–232
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
E. Stegemann gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Stegemann, E. Interdisziplinäre Zusammenarbeit bei Vaskulitiden . Gefässchirurgie 24, 99–103 (2019). https://doi.org/10.1007/s00772-019-0505-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00772-019-0505-1